Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 18, Pages 4474
Publisher
MDPI AG
Online
2019-09-11
DOI
10.3390/ijms20184474
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
- (2019) Martha Foltyn et al. BRITISH JOURNAL OF CANCER
- High USP6NL levels in breast cancer sustain chronic AKT phosphorylation and GLUT1 stability fueling aerobic glycolysis
- (2018) Daniele Avanzato et al. CANCER RESEARCH
- SOD1 Phosphorylation by mTORC1 Couples Nutrient Sensing and Redox Regulation
- (2018) Chi Kwan Tsang et al. MOLECULAR CELL
- mTOR inhibition in glioblastoma: requiem for a dream?
- (2018) Sam Babak et al. NEURO-ONCOLOGY
- OUP accepted manuscript
- (2018) NEURO-ONCOLOGY
- Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
- (2018) Michael W. Ronellenfitsch et al. Acta Neuropathologica Communications
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1
- (2017) Masahiro Morita et al. MOLECULAR CELL
- A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
- (2017) Prakash Chinnaiyan et al. NEURO-ONCOLOGY
- Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
- (2016) W. Wick et al. CLINICAL CANCER RESEARCH
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells
- (2016) Suratchanee Phadngam et al. Oncotarget
- NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
- (2015) Zhiyun Yu et al. CANCER LETTERS
- Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
- (2013) Q. Liu et al. CANCER RESEARCH
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy
- (2013) M. Weiler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- A unifying model for mTORC1-mediated regulation of mRNA translation
- (2012) Carson C. Thoreen et al. NATURE
- Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy
- (2011) Arunkumar Anandharaj et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer
- (2011) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death
- (2011) C Wanka et al. ONCOGENE
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives
- (2010) Michael W. Ronellenfitsch et al. Targeted Oncology
- The tuberous sclerosis complex
- (2009) Ksenia A. Orlova et al. Annals of the New York Academy of Sciences
- Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death
- (2009) Michael W. Ronellenfitsch et al. BRAIN
- ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy
- (2009) Ian G. Ganley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
- (2008) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now